Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Share-based Compensation: 2009-2025

Historic Share-based Compensation for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Sep 2025 value amounting to $81,262.

  • Cumberland Pharmaceuticals' Share-based Compensation rose 6.40% to $81,262 in Q3 2025 from the same period last year, while for Sep 2025 it was $310,972, marking a year-over-year decrease of 3.12%. This contributed to the annual value of $301,895 for FY2024, which is 17.30% down from last year.
  • According to the latest figures from Q3 2025, Cumberland Pharmaceuticals' Share-based Compensation is $81,262, which was up 0.71% from $80,686 recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' Share-based Compensation registered a high of $224,786 during Q4 2021, and its lowest value of -$27,753 during Q2 2022.
  • Over the past 3 years, Cumberland Pharmaceuticals' median Share-based Compensation value was $80,686 (recorded in 2025), while the average stood at $82,100.
  • In the last 5 years, Cumberland Pharmaceuticals' Share-based Compensation plummeted by 114.46% in 2022 and then soared by 452.68% in 2023.
  • Quarterly analysis of 5 years shows Cumberland Pharmaceuticals' Share-based Compensation stood at $224,786 in 2021, then slumped by 43.54% to $126,905 in 2022, then fell by 26.01% to $93,894 in 2023, then declined by 20.32% to $74,812 in 2024, then climbed by 6.40% to $81,262 in 2025.
  • Its last three reported values are $81,262 in Q3 2025, $80,686 for Q2 2025, and $74,212 during Q1 2025.